Federico Cappuzzo

Address Director of Oncology and Hematology Department
AUSL della Romagna-Ravenna



Dr Federico Cappuzzo has been the Director of Medical Oncology at AUSL della Romagna-Ravenna since April 2016 and since January 2017 he is the Director of the Hematology and Oncology Department.

In November 1992, he graduated, summa cum laude, in Medicine and Surgery at the Palermo University and in November 1996, yielded a Degree summa cum laude in Medical Oncology at the Milan University, followed by the ESMO (European Society for Medical Oncology) certification in Medical Oncology in 1997.

From 1997 to 1999 he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris), followed by attendance at the Thoracic Oncology Unit at the Medical University of South Carolina in Charleston (USA) from April to September 2000.

For six years, from November 2000 to 2006, he was assistant professor at the Ospedale Bellaria in Bologna, Italy, and from January to November 2004 he was visiting associate professor in Medical Oncology at the University of Colorado in Denver (USA).

From November 2006 to January 2010 he was assistant professor in Medical Oncology at the Istituto Clinico Humanitas IRCCS in Rozzano (Milan), Italy, and from January 2010 to April 2016 he was the Director of the Medical Oncology Department at the Istituto Toscano Tumori-Ospedale Civile in Livorno, Italy.

Dr Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the International Association for the Study of Lung Cancer (IASCL) and since 2006 he has been a member of the editorial board of Lung Cancer.  Since January 2016 he has been the Chairman of the Educational Committee of IASLC.

In 2006, 2009 and 2012 Dr Cappuzzo received research grants from the Italian Association for Cancer Research (AIRC) on targeted therapies in lung cancer.

He is the author of more than 200 papers in peer-review journals, mainly in translational research in lung cancer.